S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis

Aytu BioPharma (AYTU) Earnings Date, Estimates & Call Transcripts

$2.79
0.00 (0.00%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 9Estimated
Actual EPS
(Feb. 14)
-$0.04 Missed By -$0.04
Skip Charts & View Estimated and Actual Earnings Data

AYTU Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AYTU Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

AYTU Earnings Date and Information

Aytu BioPharma last issued its quarterly earnings data on February 14th, 2024. The reported ($0.04) EPS for the quarter. The company earned $22.93 million during the quarter. Aytu BioPharma has generated ($4.04) earnings per share over the last year (($4.04) diluted earnings per share). Aytu BioPharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.

Aytu BioPharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Estimated)
------- 
2/14/2024Q2 2024-($0.04)($0.04)($0.04)-$22.93 million
11/14/2023Q1 2024-($1.48)($1.48)($1.48)-$22.10 million
9/27/2023Q4 2023-$0.16+$0.16$0.91-$30.73 million
5/11/2023Q3 2023-($1.93)($1.93)($1.93)-$22.73 million
2/21/2023Q2 2023$0.20($1.31)($1.51)($0.47)$32.60 million$26.28 million
11/14/2022Q1 2023-($1.20)($1.20)($1.20)-$27.66 million
9/27/2022Q4 2022($0.24)($0.25)($0.01)($0.01)$25.70 million$27.45 million
5/16/2022Q3 2022($0.41)($0.27)+$0.14$1.25$24.20 million$24.20 million
2/13/2022Q2 2022($0.58)($0.44)+$0.14($0.44)-$23.13 million
11/15/2021Q3 2021($0.49)($1.09)($0.60)$0.43-$21.90 million    
9/26/2021Q2 2021($0.49)($0.75)($0.26)($0.53)$24.50 million$23.48 million    
5/16/2021Q1 2021($0.36)($1.41)($1.05)$1.07$14.10 million$13.48 million  

Aytu BioPharma Earnings - Frequently Asked Questions

When is Aytu BioPharma's earnings date?

Aytu BioPharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on AYTU's earnings history.

How much revenue does Aytu BioPharma generate each year?

Aytu BioPharma (NASDAQ:AYTU) has a recorded annual revenue of $107.40 million.

How much profit does Aytu BioPharma generate each year?

Aytu BioPharma (NASDAQ:AYTU) has a recorded net income of -$17.05 million. AYTU has generated -$4.04 earnings per share over the last four quarters.


More Earnings Resources from MarketBeat

This page (NASDAQ:AYTU) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners